Gloria N. Mattiuzzi, Jorge E. Cortes, Deborah A. Blamble, B. Nebiyou Bekele, Lianchun Xiao, Maria Cabanillas, Gautam Borthakur, Susan O'Brien and Hagop Kantarjian Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia Cancer 116
Version of Record online: 31 AUG 2010 | DOI: 10.1002/cncr.25365
Nausea and vomiting in acute myelogenous leukemia (AML) patients can be from various causes, including the use of high-dose cytarabine. This study, the first prospective randomized trial of medications for the prevention of chemotherapy-induced nausea and vomiting in AML or high-risk myelodysplastic syndrome patients, suggests that palonosetron given daily for up to 5 days significantly reduced the incidence and severity of nausea on Days 6 and 7.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field